Pepgen Inc. (PEPG) Stock Price & Analysis
Pepgen Inc. (PEPG) fell 8.10% to USD 1.93 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
PEPG last closed at USD 2.1; the session ranged USD 1.92–2.18 on volume of 732,153 shares. Market capitalization is $133.50M, with a 52-week range of USD 1.01–7.8 (NMS). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 1.93 |
|---|---|
| Change | ▼ 8.10% (down) |
| Previous Close | USD 2.1 |
| Open | USD 2.12 |
| Day Range | USD 1.92 – 2.18 |
| 52-Week Range | USD 1.01 – 7.8 |
| Volume | 732,153 shares |
| Market Cap | $133.50M |
| Exchange | NMS |
Technical Analysis (PEPG)
Nexqual's technical model rates PEPG "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.15 (neutral) |
| vs SMA50 | Above (USD 1.76) |
| MACD | 0.09 (positive) |
Analyst Ratings (PEPG)
Wall Street analysts rate PEPG "None" based on 8 analysts, with a mean price target of USD 10.25 (range USD 3–20), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 10.25 |
| High Target | USD 20 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 7 / 0 / 1 |
Earnings (PEPG)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.29 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.27 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.57 ▲ beat |
| 2025-06-30 | USD -0.7 vs est -0.86 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (PEPG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -68.40% |
| Debt / Equity | 12.36 |
| Current Ratio | 14.98 |
| Total Cash | $132.30M |
| Total Debt | $16.56M |
| Free Cash Flow | $-49.81M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (PEPG)
Nexqual rates Pepgen Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $132M cash vs $17M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$77M |
| Efficiency | Critical — ROE -68%, ROA -35.8% |
Ownership (PEPG)
| Insider Ownership | +0.23% |
|---|---|
| Institutional Ownership | +88.36% |
| Shares Outstanding | 69.17M |
| Float | 36.05M |
| Short % of Float | +8.17% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Leadership (PEPG)
Pepgen Inc. is led by James G. McArthur (age 63), President, CEO, Treasurer, Secretary & Director, per Nexqual as of July 25, 2026 at 03:03 UTC.
| President, CEO, Treasurer, Secretary & Director | James G. McArthur (age 63) |
|---|---|
| Chief Financial Officer | Noel P. Donnelly (age 55) |
| Senior Vice President of HR & Administration | Emiko Bryant |
| Senior Vice President of Global Regulatory Affairs & Quality | Hayley Parker |
| Vice President & Head of Preclinical | Pallavi Lonkar |
Major Backers & Investors (PEPG)
Notable institutional backers of Pepgen Inc. include RA Capital Management, L.P., Commodore Capital Lp, Viking Global, according to Nexqual as of July 25, 2026 at 03:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 29.01% |
| Commodore Capital Lp | 6.47% |
| Viking Global | 5.03% |
| Laurion Capital Management, LP | 3.98% |
| Vivo Capital, LLC | 3.36% |
| Millennium Management | 3.01% |
| AWM Investment Company, Inc. | 2.65% |
| Adar1 Capital Management, LLC | 2.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.54% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
From Pepgen Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
- The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
- It is also involved in FREEDOM-OLE, an open label expansion study.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
| MLYS | Mineralys Therapeutics, Inc. | USD 26.71 | ▼ 1.11% |
| ACRV | Acrivon Therapeutics, Inc. | USD 1.6 | ▼ 4.76% |
| TYRA | Tyra Biosciences, Inc. | USD 30.63 | ▲ 0.13% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.